SciSparc’s Promising Clinical Study on SCI-210 for Autism Spectrum Disorder
SciSparc Ltd. ((SPRC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. is currently conducting a clinical study titled ‘A Randomized, Double-Blind, Sparing-effect Placebo Controlled, With Cross-over Study to Evaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD).’ The study aims to assess the safety and efficacy of SCI-210, a treatment for Autism Spectrum Disorder (ASD), which could provide significant advancements in managing this condition.
The intervention being tested is SCI-210, which consists of oral CBD oil combined with CannAmide (palmitoylethanolamide, PEA) pills. This treatment is designed to enhance the therapeutic effects of CBD oil in treating ASD symptoms.
The study follows an interventional design with a randomized, crossover model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on November 29, 2021, and is currently recruiting participants. The last update was submitted on May 13, 2025, indicating ongoing progress. These dates are crucial as they mark the study’s timeline and its current status in the clinical trial process.
The update on this study could influence SciSparc’s stock performance positively, as successful results may enhance investor confidence and market interest. In the competitive landscape, advancements in ASD treatment could position SciSparc favorably against other pharmaceutical companies exploring similar therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.
